I doubt whether you are alone in wondering whether the...

I doubt whether you are alone in wondering whether the combination of FPP-Omomyc with a PD-L1 inhibitor will create a synergistic effect. IO is turning to combination therapy to improve results for the many rather than the few. Big Pharma is going for broke in trialling all manner of combinations.

FPP-Omomyc (or equivalent iMYC) combined with a PD-L1 inhibitor could go top of the list if Stanford is correct with its research.

The application of Myc in immuno-oncology changes the way we think about the mechanism of action. By targeting immune suppression pathways rather than the tumor, the sink effect may be less of a problem. Just to recap, BioExec in his excellent post of 21/02/2016 wrote;

"They chose Myc, my guess in part, because Omomyc, surprisingly appears to have no effect if it gets into normal cells. If true, and it looks like it is, that would be great, dont have to worry about the side effects from off-target. This doesnt alleviate the sink effect, but at least if it is accumulating in other cells it shouldnt do anything bad."

Of course, as you say, there is only one approved PD-L1 - Tecentriq (Atezolizumab) by Genentech. Its a small world.